12/2
03:46 pm
tgtx
TG Therapeutics (NASDAQ:TGTX) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
TG Therapeutics (NASDAQ:TGTX) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
11/28
07:30 am
tgtx
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Low
Report
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
11/26
02:20 pm
tgtx
TG Therapeutics (NASDAQ:TGTX) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
TG Therapeutics (NASDAQ:TGTX) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
08:30 am
tgtx
TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies
Medium
Report
TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies
11/18
02:25 am
tgtx
TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing [Seeking Alpha]
Low
Report
TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing [Seeking Alpha]
11/10
04:00 pm
tgtx
TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
Low
Report
TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
11/5
07:32 am
tgtx
TG Therapeutics (NASDAQ:TGTX) was upgraded by analysts at B. Riley to a "strong-buy" rating.
Low
Report
TG Therapeutics (NASDAQ:TGTX) was upgraded by analysts at B. Riley to a "strong-buy" rating.
11/3
11:03 am
tgtx
TG Therapeutics (NASDAQ:TGTX) had its price target raised by analysts at JPMorgan Chase & Co. from $46.00 to $49.00. They now have an "overweight" rating on the stock.
Low
Report
TG Therapeutics (NASDAQ:TGTX) had its price target raised by analysts at JPMorgan Chase & Co. from $46.00 to $49.00. They now have an "overweight" rating on the stock.
11/3
07:00 am
tgtx
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
Medium
Report
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
10/31
07:30 am
tgtx
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
Low
Report
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
10/28
07:30 am
tgtx
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
Low
Report
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
10/25
12:13 pm
tgtx
TG Therapeutics (NASDAQ:TGTX) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
TG Therapeutics (NASDAQ:TGTX) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
10/7
07:54 am
tgtx
TG Therapeutics (NASDAQ:TGTX) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Low
Report
TG Therapeutics (NASDAQ:TGTX) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
10/6
08:01 am
tgtx
TG Therapeutics (NASDAQ:TGTX) was given a new $60.00 price target on by analysts at HC Wainwright.
Low
Report
TG Therapeutics (NASDAQ:TGTX) was given a new $60.00 price target on by analysts at HC Wainwright.
10/4
11:09 am
tgtx
Institutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$176m market cap gain [Yahoo! Finance]
Low
Report
Institutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$176m market cap gain [Yahoo! Finance]
10/4
10:45 am
tgtx
What TG Therapeutics (TGTX)'s Six-Year BRIUMVI Safety Data Means For Shareholders [Yahoo! Finance]
Low
Report
What TG Therapeutics (TGTX)'s Six-Year BRIUMVI Safety Data Means For Shareholders [Yahoo! Finance]
9/24
09:10 am
tgtx
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
Low
Report
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
9/22
11:10 am
tgtx
Neuraxpharm participates in ECTRIMS, reinforcing its commitment to multiple sclerosis [Yahoo! Finance]
Low
Report
Neuraxpharm participates in ECTRIMS, reinforcing its commitment to multiple sclerosis [Yahoo! Finance]
9/17
02:39 pm
tgtx
TG Therapeutics (NASDAQ:TGTX) had its price target raised by analysts at B. Riley from $53.00 to $55.00. They now have a "buy" rating on the stock.
Low
Report
TG Therapeutics (NASDAQ:TGTX) had its price target raised by analysts at B. Riley from $53.00 to $55.00. They now have a "buy" rating on the stock.
9/10
07:51 am
tgtx
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting [Yahoo! Finance]
Low
Report
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting [Yahoo! Finance]
9/10
07:30 am
tgtx
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Low
Report
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
9/8
07:43 am
tgtx
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment [Yahoo! Finance]
Low
Report
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment [Yahoo! Finance]
9/8
07:30 am
tgtx
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
Low
Report
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
9/7
08:54 am
tgtx
Why TG Therapeutics (TGTX) Is Up 9.8% After Launching Another $100 Million Buyback Program [Yahoo! Finance]
Low
Report
Why TG Therapeutics (TGTX) Is Up 9.8% After Launching Another $100 Million Buyback Program [Yahoo! Finance]